Freedom of Information

Title
Prescribing: Haemophilia A
Reference Number
RF23-496
Request Details

Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as paediatric (age 17 and under).

Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?
• Advate
• Adynovi
• Elocta
• Esperoct
• Factor Eight Inhibitor Bypass Activity (FEIBA)
• Hemlibra (standalone)
• Hemlibra in combination with any Factor VIII
• NovoEight
• NovoSeven RT
• Nuwiq
• Obizur
• Refacto AF
• Any other products

Q3. For patients treated with Advate in the last three months, please provide:
• the number of haemophilia A patients treated prophylactically
• the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)

Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?
• Advate
• Adynovi
• Elocta
• Esperoct
• Factor Eight Inhibitor Bypass Activity (FEIBA)
• Hemlibra (standalone)
• Hemlibra in combination with any Factor VIII
• NovoEight
• NovoSeven RT
• Nuwiq
• Obizur
• Refacto AF
• Any other products

Response
  • rf23-496-response.pdf
    • Date of Disclosure
    18/08/2023